Aptose Biosciences Inc. logo
Aptose to Release First Quarter Ended March 31, 2020 Financial Results and Hold Conference Call on May 5, 2020
21 avr. 2020 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Fourth Quarter and Full Year 2019
10 mars 2020 16h02 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Inc. logo
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020
25 févr. 2020 07h31 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference
29 janv. 2020 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference
07 janv. 2020 07h30 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Announces Closing of Public Offering of Common Shares
19 déc. 2019 16h02 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
Aptose Biosciences Inc. logo
Aptose Announces Pricing of Public Offering of Common Shares
17 déc. 2019 08h00 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
Aptose Biosciences Inc. logo
Aptose Announces Proposed Public Offering of Common Shares
16 déc. 2019 16h19 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public...
Aptose Biosciences Inc. logo
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
09 déc. 2019 11h00 HE | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Biosciences Inc. logo
Aptose Presents Highlights From Corporate Event At ASH
07 déc. 2019 11h00 HE | Aptose Biosciences, Inc.
SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at...